Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Operating Expenses (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Operating Expenses for 5 consecutive years, with $61.8 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Expenses fell 40.4% year-over-year to $61.8 million; the TTM value through Mar 2026 reached $270.6 million, down 24.19%, while the annual FY2025 figure was $312.5 million, 3.77% down from the prior year.
  • Operating Expenses hit $61.8 million in Q1 2026 for Phathom Pharmaceuticals, up from $55.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $103.7 million in Q1 2025 and bottomed at $30.1 million in Q1 2023.
  • Average Operating Expenses over 5 years is $61.1 million, with a median of $58.6 million recorded in 2025.
  • Year-over-year, Operating Expenses surged 162.6% in 2024 and then crashed 40.4% in 2026.
  • Phathom Pharmaceuticals' Operating Expenses stood at $46.6 million in 2022, then skyrocketed by 50.92% to $70.4 million in 2023, then grew by 21.13% to $85.3 million in 2024, then tumbled by 34.48% to $55.9 million in 2025, then grew by 10.59% to $61.8 million in 2026.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $61.8 million, $55.9 million, and $58.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.